![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sanders, Cummings Launch Congressional Investigation into Marathon’s $89,000 Drug
Sanders, Cummings Launch Congressional Investigation into Marathon’s $89,000 Drug
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/Capitol.jpg?t=1433873163&width=430)
February 17, 2017
Two congressmen sent a letter to the CEO of Marathon Pharmaceuticals, calling the company’s decision to market an old drug for Duchenne muscular dystrophy for $89,000 per year “outrageous” and “unconscionable.”
Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.) urged the company to significantly lower its price for Emflaza (deflazacort) — which had been previously available in Canada and the United Kingdom for years at an annual cost of about $1,000 — and said that they would launch an investigation.
Upcoming Events
-
21Oct